Objectives The aim of our study was to evaluate the effectiveness and tolerability of
perampanel (PER) as first add-on and as second line monotherapy in subjects with …

Objectives Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) glutamate receptor antagonist recently approved for focal …

Purpose The purpose of this study was to evaluate the effectiveness and safety of PER as
add-on treatment in patients with severe refractory epilepsy with a particular focus on …

Perampanel, a non-competitive AMPA receptor antagonist, is a once-daily oral antiepileptic
drug approved for the treatment of focal seizures and primary generalized tonic–clonic …

Aim There are few reports on the tolerability and efficacy of perampanel, a new antiepileptic
drug with a novel mechanism of action, in children and adolescents. We aimed to describe …

Aim To assess the clinical trial and real‐world data for adjunctive perampanel in
adolescents and develop consensus recommendations to guide the use of perampanel in …

Introduction Perampanel is an AMPA receptor antagonist recently approved for the treatment
of partial and generalized epilepsies with tonic–clonic seizures as an add-on therapy …

Objective The aim of this study was to evaluate long-term effects of adjunctive perampanel
on cognition, efficacy, growth, safety, and tolerability in adolescents with inadequately …

Purpose The objective of this work was to review systematically the efficacy and tolerability
of perampanel (PER) in residential patients of an epilepsy center. Method We adopted an …

Objective Perampanel (PER) is indicated as adjunctive antiseizure medication (ASM) in
adolescents and adults with epilepsy. Data from clinical trials show good efficacy and …